20 results on '"Zsótér N"'
Search Results
2. Automatic vertebra labeling using SPECT/CT images
- Author
-
Barta, B, additional, Urbán, S, additional, Besenyi, Z, additional, Pávics, L, additional, Zsótér, N, additional, and Csirik, J, additional
- Published
- 2020
- Full Text
- View/download PDF
3. Tumorheterogenität in der DOTATOC-PET/CT als Biomarker bei neuroendokrinen Tumoren
- Author
-
Heß, V, additional, Bundschuh, RA, additional, Essler, M, additional, and Zsótér, N, additional
- Published
- 2019
- Full Text
- View/download PDF
4. Fully automatic quotient image generation using V/Q SPECT/CT images
- Author
-
Herdinai, K, additional, Urbán, S, additional, Besenyi, Z, additional, Pávics, L, additional, Zsótér, N, additional, and Csirik, J, additional
- Published
- 2019
- Full Text
- View/download PDF
5. Fully automatic motion correction on dynamic renal scintigraphy
- Author
-
Hirling, D, additional, Urbán, S, additional, Besenyi, Z, additional, Pávics, L, additional, Zsótér, N, additional, and Csirik, J, additional
- Published
- 2019
- Full Text
- View/download PDF
6. Fully automatic lung lobe segmentation using V/Q SPECT/CT images.
- Author
-
Király, A, Urbán, S, Besenyi, Z, Pávics, L, Zsótér, N, and Csirik, J
- Published
- 2020
- Full Text
- View/download PDF
7. Automatic vertebra labeling using SPECT/CT images.
- Author
-
Barta, B, Urbán, S, Besenyi, Z, Pávics, L, Zsótér, N, and Csirik, J
- Published
- 2020
- Full Text
- View/download PDF
8. Fully automatic motion correction on dynamic renal scintigraphy
- Author
-
Hirling, D, Urbán, S, Besenyi, Z, Pávics, L, Zsótér, N, and Csirik, J
- Published
- 2019
- Full Text
- View/download PDF
9. Fully automatic quotient image generation using V/Q SPECT/CT images
- Author
-
Herdinai, K, Urbán, S, Besenyi, Z, Pávics, L, Zsótér, N, and Csirik, J
- Published
- 2019
- Full Text
- View/download PDF
10. Tumorheterogenität in der DOTATOC-PET/CT als Biomarker bei neuroendokrinen Tumoren
- Author
-
Heß, V, Bundschuh, RA, Essler, M, and Zsótér, N
- Published
- 2019
- Full Text
- View/download PDF
11. Tumor heterogeneity for differentiation between liver tumors and normal liver tissue in 18F-FDG PET/CT.
- Author
-
Hartmann L, Bundschuh L, Zsótér N, Essler M, and Bundschuh RA
- Abstract
Aim: Malignancies show higher spatial heterogeneity than normal tissue. We investigated, if textural parameters from FDG PET describing the heterogeneity function as tool to differentiate between tumor and normal liver tissue., Methods: FDG PET/CT scans of 80 patients with liver metastases and 80 patients with results negative upper abdominal organs were analyzed. Metastases and normal liver tissue were analyzed drawing up to three VOIs with a diameter of 25 mm in healthy liver tissue of the tumoral affected and results negative liver, whilst up to 3 metastases per patient were delineated. Within these VOIs 30 different textural parameters were calculated as well as SUV. The parameters were compared in terms of intra-patient and inter-patient variability (2-sided t test). ROC analysis was performed to analyze predictive power and cut-off values., Results: 28 textural parameters differentiated healthy and pathological tissue (p < 0.05) with high sensitivity and specificity. SUV showed ability to differentiate but with a lower significance. 15 textural parameters as well as SUV showed a significant variation between healthy tissues out of tumour infested and negative livers. Mean intra- and inter-patient variability of metastases were found comparable or lower for 6 of the textural features than the ones of SUV. They also showed good values of mean intra- and inter-patient variability of VOIs drawn in liver tissue of patients with metastases and of results negative ones., Conclusion: Heterogeneity parameters assessed in FDG PET are promising to classify tissue and differentiate malignant lesions usable for more personalized treatment planning, therapy response evaluation and precise delineation of tumors for target volume determination as part of radiation therapy planning., Competing Interests: RB is Consultant for Bayer Healthcare (Leverkusen, Germany) and Eisai GmbH (Frankfurt, Germany). RB has a non-commercial research agreement and is on the speakers list with Mediso Medical Imaging (Budapest, Hungary)ME is Consultant for Consultant for Bayer Healthcare (Leverkusen, Germany) and Eisai GmbH (Frankfurt, Germany), IPSEN and Novartis.The results presented in this paper are part of the doctoral thesis of Lynn Hartmann submitted at the Rheinische Friedrich-Wilhelm-Universität, Bonn, Germany., (Thieme. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
12. Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
- Author
-
Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, Muegge DO, Javadi MS, Higuchi T, Buck AK, Bartenstein P, Bengel F, Essler M, Lapa C, and Bundschuh RA
- Subjects
- Cohort Studies, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Probability, ROC Curve, Risk, Neuroendocrine Tumors radiotherapy, Pancreatic Neoplasms radiotherapy, Radioisotopes therapeutic use, Receptors, Peptide therapeutic use, Receptors, Somatostatin metabolism
- Abstract
Purpose: Early identification of aggressive disease could improve decision support in pancreatic neuroendocrine tumor (pNET) patients prior to peptide receptor radionuclide therapy (PRRT). The prognostic value of intratumoral textural features (TF) determined by baseline somatostatin receptor (SSTR)-positron emission tomography (PET) before PRRT was analyzed., Procedures: Thirty-one patients with G1/G2 pNET were enrolled (G2, n = 23/31). Prior to PRRT with [
177 Lu]DOTATATE (mean, 3.6 cycles), baseline SSTR-PET computed tomography was performed. By segmentation of 162 (median per patient, 5) metastases, intratumoral TF were computed. The impact of conventional PET parameters (SUVmean/max ), imaging-based TF, and clinical parameters (Ki67, CgA) for prediction of both progression-free survival (PFS) and overall survival (OS) after PRRT were evaluated., Results: Within a median follow-up of 3.7 years, tumor progression was detected in 21 patients (median, 1.5 years) and 13/31 deceased (median, 1.9 years). In ROC analysis, the TF entropy, reflecting derangement on a voxel-by-voxel level, demonstrated predictive capability for OS (cutoff = 6.7, AUC = 0.71, p = 0.02). Of note, increasing entropy could predict a longer survival (> 6.7, OS = 2.5 years, 17/31), whereas less voxel-based derangement portended inferior outcome (< 6.7, OS = 1.9 years, 14/31). These findings were supported in a G2 subanalysis (> 6.9, OS = 2.8 years, 9/23 vs. < 6.9, OS = 1.9 years, 14/23). Kaplan-Meier analysis revealed a significant distinction between high- and low-risk groups using entropy (n = 31, p < 0.05). For those patients below the ROC-derived threshold, the relative risk of death after PRRT was 2.73 (n = 31, p = 0.04). Ki67 was negatively associated with PFS (p = 0.002); however, SUVmean/max failed in prognostication (n.s.)., Conclusions: In contrast to conventional PET parameters, assessment of intratumoral heterogeneity demonstrated superior prognostic performance in pNET patients undergoing PRRT. This novel PET-based strategy of outcome prediction prior to PRRT might be useful for patient risk stratification.- Published
- 2019
- Full Text
- View/download PDF
13. Volumetric and texture analysis of pretherapeutic 18 F-FDG PET can predict overall survival in medullary thyroid cancer patients treated with Vandetanib.
- Author
-
Werner RA, Bundschuh RA, Higuchi T, Javadi MS, Rowe SP, Zsótér N, Kroiss M, Fassnacht M, Buck AK, Kreissl MC, and Lapa C
- Subjects
- Carcinoma, Neuroendocrine pathology, Carcinoma, Neuroendocrine ultrastructure, Follow-Up Studies, Humans, Neoplasm Staging, Predictive Value of Tests, Prognosis, Progression-Free Survival, Retrospective Studies, Sensitivity and Specificity, Thyroid Neoplasms pathology, Thyroid Neoplasms ultrastructure, Treatment Outcome, Carcinoma, Neuroendocrine diagnosis, Carcinoma, Neuroendocrine drug therapy, Fluorodeoxyglucose F18, Piperidines therapeutic use, Positron Emission Tomography Computed Tomography, Quinazolines therapeutic use, Thyroid Neoplasms diagnosis, Thyroid Neoplasms drug therapy, Tumor Burden
- Abstract
Purpose: The metabolically most active lesion in 2-deoxy-2-(
18 F)fluoro-D-glucose (18 F-FDG) PET/CT can predict progression-free survival (PFS) in patients with medullary thyroid carcinoma (MTC) starting treatment with the tyrosine kinase inhibitor (TKI) vandetanib. However, this metric failed in overall survival (OS) prediction. In the present proof of concept study, we aimed to explore the prognostic value of intratumoral textural features (TF) as well as volumetric parameters (total lesion glycolysis, TLG) derived by pre-therapeutic18 F-FDG PET., Methods: Eighteen patients with progressive MTC underwent baseline18 F-FDG PET/CT prior to and 3 months after vandetanib initiation. By manual segmentation of the tumor burden at baseline and follow-up PET, intratumoral TF and TLG were computed. The ability of TLG, imaging-based TF, and clinical parameters (including age, tumor marker doubling times, prior therapies and RET (rearranged during transfection) mutational status) for prediction of both PFS and OS were evaluated., Results: The TF Complexity and the volumetric parameter TLG obtained at baseline prior to TKI initiation successfully differentiated between low- and high-risk patients. Complexity allocated 10/18 patients to the high-risk group with an OS of 3.3 y (vs. low-risk group, OS = 5.3 y, 8/18, AUC = 0.78, P = 0.03). Baseline TLG designated 11/18 patients to the high-risk group (OS = 3.5 y vs. low-risk group, OS = 5 y, 7/18, AUC = 0.83, P = 0.005). The Hazard Ratio for cancer-related death was 6.1 for Complexity (TLG, 9.5). Among investigated clinical parameters, the age at initiation of TKI treatment reached significance for PFS prediction (P = 0.02, OS, n.s.)., Conclusions: The TF Complexity and the volumetric parameter TLG are both independent parameters for OS prediction.- Published
- 2019
- Full Text
- View/download PDF
14. Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.
- Author
-
Werner RA, Ilhan H, Lehner S, Papp L, Zsótér N, Schatka I, Muegge DO, Javadi MS, Higuchi T, Buck AK, Bartenstein P, Bengel F, Essler M, Lapa C, and Bundschuh RA
- Abstract
The article "Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy," was originally published electronically on the publisher's internet portal without open access.
- Published
- 2018
- Full Text
- View/download PDF
15. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity.
- Author
-
Werner RA, Lapa C, Ilhan H, Higuchi T, Buck AK, Lehner S, Bartenstein P, Bengel F, Schatka I, Muegge DO, Papp L, Zsótér N, Große-Ophoff T, Essler M, and Bundschuh RA
- Subjects
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Neuroendocrine Tumors diagnostic imaging, Neuroendocrine Tumors metabolism, Octreotide administration & dosage, Octreotide therapeutic use, Organometallic Compounds therapeutic use, Prognosis, ROC Curve, Treatment Outcome, Neuroendocrine Tumors radiotherapy, Octreotide analogs & derivatives, Organometallic Compounds administration & dosage, Positron Emission Tomography Computed Tomography methods, Receptors, Somatostatin metabolism
- Abstract
The NETTER-1 trial demonstrated significantly improved progression-free survival (PFS) for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET) emphasizing the high demand for response prediction in appropriate candidates. In this multicenter study, we aimed to elucidate the prognostic value of tumor heterogeneity as assessed by somatostatin receptor (SSTR)-PET/CT. 141 patients with SSTR-expressing tumors were analyzed obtaining SSTR-PET/CT before PRRT (1-6 cycles, 177Lu somatostatin analog). Using the Interview Fusion Workstation (Mediso), a total of 872 metastases were manually segmented. Conventional PET parameters as well as textural features representing intratumoral heterogeneity were computed. The prognostic ability for PFS and overall survival (OS) were examined. After performing Cox regression, independent parameters were determined by ROC analysis to obtain cut-off values to be used for Kaplan-Meier analysis. Within follow-up (median, 43.1 months), 75 patients showed disease progression (median, 22.2 m) and 54 patients died (median, 27.6 m). Cox analysis identified 8 statistically independent heterogeneity parameters for time-to-progression and time-to-death. Among them, the textural feature Entropy predicted both PFS and OS. Conventional PET parameters failed in response prediction. Imaging-based heterogeneity assessment provides prognostic information in PRRT candidates and outperformed conventional PET parameters. Its implementation in clinical practice can pave the way for individualized patient management.
- Published
- 2017
- Full Text
- View/download PDF
16. A study on the value of computer-assisted assessment for SPECT/CT-scans in sentinel lymph node diagnostics of penile cancer as well as clinical reliability and morbidity of this procedure.
- Author
-
Lützen U, Naumann CM, Marx M, Zhao Y, Jüptner M, Baumann R, Papp L, Zsótér N, Aksenov A, Jünemann KP, and Zuhayra M
- Subjects
- Adult, Aged, Humans, Image-Guided Biopsy methods, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Penile Neoplasms pathology, Reproducibility of Results, Sentinel Lymph Node Biopsy methods, Image-Guided Biopsy adverse effects, Multimodal Imaging, Penile Neoplasms diagnostic imaging, Sentinel Lymph Node Biopsy adverse effects, Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed
- Abstract
Background: Because of the increasing importance of computer-assisted post processing of image data in modern medical diagnostic we studied the value of an algorithm for assessment of single photon emission computed tomography/computed tomography (SPECT/CT)-data, which has been used for the first time for lymph node staging in penile cancer with non-palpable inguinal lymph nodes. In the guidelines of the relevant international expert societies, sentinel lymph node-biopsy (SLNB) is recommended as a diagnostic method of choice. The aim of this study is to evaluate the value of the afore-mentioned algorithm and in the clinical context the reliability and the associated morbidity of this procedure., Methods: Between 2008 and 2015, 25 patients with invasive penile cancer and inconspicuous inguinal lymph node status underwent SLNB after application of the radiotracer Tc-99m labelled nanocolloid. We recorded in a prospective approach the reliability and the complication rate of the procedure. In addition, we evaluated the results of an algorithm for SPECT/CT-data assessment of these patients., Results: SLNB was carried out in 44 groins of 25 patients. In three patients, inguinal lymph node metastases were detected via SLNB. In one patient, bilateral lymph node recurrence of the groins occurred after negative SLNB. There was a false-negative rate of 4 % in relation to the number of patients (1/25), resp. 4.5 % in relation to the number of groins (2/44). Morbidity was 4 % in relation to the number of patients (1/25), resp. 2.3 % in relation to the number of groins (1/44). The results of computer-assisted assessment of SPECT/CT data for sentinel lymph node (SLN)-diagnostics demonstrated high sensitivity of 88.8 % and specificity of 86.7 %., Conclusions: SLNB is a very reliable method, associated with low morbidity. Computer-assisted assessment of SPECT/CT data of the SLN-diagnostics shows high sensitivity and specificity. While it cannot replace the assessment by medical experts, it can still provide substantial supplement and assistance.
- Published
- 2016
- Full Text
- View/download PDF
17. Assessment of tumor heterogeneity in treatment-naïve adrenocortical cancer patients using (18)F-FDG positron emission tomography.
- Author
-
Werner RA, Kroiss M, Nakajo M, Mügge DO, Hahner S, Fassnacht M, Schirbel A, Bluemel C, Higuchi T, Papp L, Zsótér N, Buck AK, Bundschuh RA, and Lapa C
- Subjects
- Adolescent, Adrenal Cortex Neoplasms pathology, Adrenocortical Carcinoma pathology, Adult, Aged, Female, Fluorodeoxyglucose F18, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Tumor Burden, Young Adult, Adrenal Cortex Neoplasms diagnostic imaging, Adrenocortical Carcinoma diagnostic imaging, Positron-Emission Tomography
- Abstract
As an orphan malignancy, only limited treatment options are available in adrenocortical carcinoma (ACC). Non-invasive risk assessment has not been described but may be of value to stratify patients for treatment. We aimed to evaluate the potential value of intra-individual tumor heterogeneity as assessed by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography/computed tomography (PET/CT) for outcome prediction in treatment-naïve ACC patients. Ten patients with primary diagnosis of ACC were included in this study. Prior to any treatment initiation, baseline (18)F-FDG PET scans were performed. Tumor staging was performed using the European Network for the Study of Adrenal Tumors (ENS@T). Intratumoral heterogeneity of the primary tumor was assessed by manual segmentation using conventional PET parameters (standardized uptake values and tumor-to-liver ratios) and textural features. The impact of tumoral heterogeneity based on pre-therapeutic (18)F-FDG PET to predict progression-free (PFS) and overall survival (OS) was evaluated by receiver operating characteristic analysis. On average, tumor recurrence or progression was detected after median of 561 days (range 71-1434 days) after the pre-therapeutic baseline PET scan. 50 % of the patients died of ACC within the follow-up period (mean 983 ± 404 days). Pre-therapeutic tumor volume was associated with PFS (r = -0.67, p = 0.05) and Ki67 index with OS (r = -0.66, p = 0.04). ENS@T tumor stage was the only parameter to correlate with both PFS and OS (r = -0.82, p = 0.001, and r = -0.72, p = 0.01, respectively). In the subgroup of patients without distant metastases (ENS@T stages II and III), age and pre-therapeutic tumor volume correlated significantly with PFS (r = 0.96, p = 0.01 and r = -0.93, p = 0.02, respectively) and OS (r = 0.95, p = 0.02 and r = -0.90, p = 0.04, respectively). None of the investigated classic or textural PET parameters predicted PFS or OS. In this pilot study in treatment-naïve ACC patients, conventional (18)F-FDG PET-derived parameters and textural tumor heterogeneity features were not suitable to identify high-risk patients.
- Published
- 2016
- Full Text
- View/download PDF
18. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy.
- Author
-
Pyka T, Bundschuh RA, Andratschke N, Mayer B, Specht HM, Papp L, Zsótér N, and Essler M
- Subjects
- Adenocarcinoma pathology, Adenocarcinoma surgery, Aged, Aged, 80 and over, Area Under Curve, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung surgery, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell surgery, Disease-Free Survival, Female, Fluorine Radioisotopes, Fluorodeoxyglucose F18, Humans, Kaplan-Meier Estimate, Lung Neoplasms pathology, Lung Neoplasms surgery, Male, Multimodal Imaging, Neoplasm Recurrence, Local, Neoplasm Staging, ROC Curve, Radiopharmaceuticals, Retrospective Studies, Adenocarcinoma diagnostic imaging, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Squamous Cell diagnostic imaging, Image Processing, Computer-Assisted, Lung Neoplasms diagnostic imaging, Positron-Emission Tomography, Tomography, X-Ray Computed
- Abstract
Background: Textural features in FDG-PET have been shown to provide prognostic information in a variety of tumor entities. Here we evaluate their predictive value for recurrence and prognosis in NSCLC patients receiving primary stereotactic radiation therapy (SBRT)., Methods: 45 patients with early stage NSCLC (T1 or T2 tumor, no lymph node or distant metastases) were included in this retrospective study and followed over a median of 21.4 months (range 3.1-71.1). All patients were considered non-operable due to concomitant disease and referred to SBRT as the primary treatment modality. Pre-treatment FDG-PET/CT scans were obtained from all patients. SUV and volume-based analysis as well as extraction of textural features based on neighborhood gray-tone difference matrices (NGTDM) and gray-level co-occurence matrices (GLCM) were performed using InterView Fusion™ (Mediso Inc., Budapest). The ability to predict local recurrence (LR), lymph node (LN) and distant metastases (DM) was measured using the receiver operating characteristic (ROC). Univariate and multivariate analysis of overall and disease-specific survival were executed., Results: 7 out of 45 patients (16%) experienced LR, 11 (24%) LN and 11 (24%) DM. ROC revealed a significant correlation of several textural parameters with LR with an AUC value for entropy of 0.872. While there was also a significant correlation of LR with tumor size in the overall cohort, only texture was predictive when examining T1 (tumor diameter < = 3 cm) and T2 (>3 cm) subgroups. No correlation of the examined PET parameters with LN or DM was shown. In univariate survival analysis, both heterogeneity and tumor size were predictive for disease-specific survival, but only texture determined by entropy was determined as an independent factor in multivariate analysis (hazard ratio 7.48, p = .016). Overall survival was not significantly correlated to any examined parameter, most likely due to the high comorbidity in our cohort., Conclusions: Our study adds to the growing evidence that tumor heterogeneity as described by FDG-PET texture is associated with response to radiation therapy in NSCLC. The results may be helpful into identifying patients who might profit from an intensified treatment regime, but need to be verified in a prospective patient cohort before being incorporated into routine clinical practice.
- Published
- 2015
- Full Text
- View/download PDF
19. Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy.
- Author
-
Lapa C, Werner RA, Schmid JS, Papp L, Zsótér N, Biko J, Reiners C, Herrmann K, Buck AK, and Bundschuh RA
- Subjects
- Adult, Aged, Disease-Free Survival, Gene Expression Regulation, Neoplastic, Humans, Iodine Radioisotopes therapeutic use, Male, Middle Aged, Peptides chemistry, Receptors, Somatostatin metabolism, Retrospective Studies, Thyroid Neoplasms diagnostic imaging, Thyroid Neoplasms metabolism, Tomography, X-Ray Computed, Peptides therapeutic use, Positron-Emission Tomography, Thyroid Neoplasms pathology, Thyroid Neoplasms radiotherapy
- Abstract
Introduction: Peptide receptor radionuclide therapy (PRRT) is a treatment option for both iodine-refractory differentiated and advanced medullary thyroid cancer (TC). It requires over-expression of somatostatin receptor subtype II (SSTR) that can be non-invasively assessed by positron emission tomography (PET). Assessment of tumor heterogeneity is increasingly used as a tool for prognostication prediction. We investigated the potential of SSTR-PET to assess intraindividual tumor heterogeneity and thereby treatment response prior to PRRT., Methods: 12 patients with progressive radioiodine-refractory differentiated (1 papillary, 1 oxyphilic, 2 oncocytic, 4 follicular) or medullary (n=4) TC were enrolled. SSTR-PET was performed at baseline. Conventional PET parameters and heterogeneity parameters were analyzed regarding their potential to predict progression-free (PFS, mean, 221 days) and overall survival (OS, mean, 450 days). Parameters of a subgroup of lesions (n=23) were also correlated with morphological response according to modified RECIST criteria., Results: In patient-based analysis, all conventional parameters failed to predict PFS. Several textural parameters showed a significant capability to assess PFS. Thereby, "Grey level non uniformity" had the highest area under the curve (AUC, 0.93) in Receiver operating characteristics analysis followed by "Contrast" (AUC, 0.89). In lesion-based analysis, only "Entropy" revealed potential to evaluate disease progression. OS could not be assessed by any parameter investigated., Conclusions: Tumor heterogeneity seems to be a predictor of response to PRRT in patients with iodine-refractory differentiated/advanced medullary thyroid cancer and outperforms conventional PET parameters like standardized uptake value. In a "theranostic" approach, assessment of textural parameters may help in selecting patients who might benefit from PRRT., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
20. Textural Parameters of Tumor Heterogeneity in ¹⁸F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer.
- Author
-
Bundschuh RA, Dinges J, Neumann L, Seyfried M, Zsótér N, Papp L, Rosenberg R, Becker K, Astner ST, Henninger M, Herrmann K, Ziegler SI, Schwaiger M, and Essler M
- Subjects
- Chemoradiotherapy, Adjuvant, Female, Humans, Kaplan-Meier Estimate, Male, Neoadjuvant Therapy, Prognosis, ROC Curve, Rectal Neoplasms diagnostic imaging, Treatment Outcome, Fluorodeoxyglucose F18, Multimodal Imaging, Positron-Emission Tomography, Rectal Neoplasms pathology, Rectal Neoplasms therapy, Tomography, X-Ray Computed
- Abstract
Unlabelled: (18)F-FDG PET/CT is effective in the assessment of therapy response. Changes in glucose uptake or tumor size are used as a measure. Tumor heterogeneity was found to be a promising predictive and prognostic factor. We investigated textural parameters for their predictive and prognostic capability in patients with rectal cancer using histopathology as the gold standard. In addition, a comparison to clinical outcome was performed., Methods: Twenty-seven patients with rectal cancer underwent (18)F-FDG PET/CT before, 2 wk after the start, and 4 wk after the completion of neoadjuvant chemoradiotherapy. In all PET/CT scans, conventional parameters (tumor volume, diameter, maximum and mean standardized uptake values, and total lesion glycolysis [TLG]) and textural parameters (coefficient of variation [COV], skewness, and kurtosis) were determined to assess tumor heterogeneity. Values on pretherapeutic PET/CT as well as changes early in the course of therapy and after therapy were compared with histopathologic response. In addition, the prognostic value was assessed by correlation with time to progression and survival time., Results: The COV showed a statistically significant capability to assess histopathologic response early in therapy (sensitivity, 68%; specificity, 88%) and after therapy (79% and 88%, respectively). Thereby, the COV had a higher area under the curve in receiver-operating-characteristic analysis than did any analyzed conventional parameter for early and late response assessment. The COV showed a statistically significant capability to evaluate disease progression and to predict survival, although the latter was not statistically significant., Conclusion: Tumor heterogeneity assessed by the COV, being superior to the investigated conventional parameters, is an important predictive factor in patients with rectal cancer. Furthermore, it can provide prognostic information. Therefore, its application is an important step for personalized treatment of rectal cancer., (© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.)
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.